Theravance Biopharma Inc (TBPH.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|57||Chairman of the Board, Chief Executive Officer|
|45||2014||Senior Vice President, Chief Financial Officer, Treasurer|
|57||2016||Executive Vice President, General Counsel, Secretary|
|47||2016||Senior Vice President - Clinical Development and Chief Medical Officer|
|53||2014||Senior Vice President, Research|
- BRIEF-Theravance Biopharma Files Supplemental NDA With U.S. FDA For Use Of Trelegy Ellipta
- BRIEF-Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD
- BRIEF-Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin
- BRIEF-Theravance Biopharma posts Q3 loss of $1.27 per share
- BRIEF-Theravance Biopharma and Mylan reports positive Phase 3 data for Revefenacin